Navitoclax, Venetoclax and Decitabine
A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 1
- Enrollment
- 16 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- AbbVie
- Tags
- BCL-2 Inhibitor, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1625
- NCT Identifier
- NCT05455294
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.